Jetstream backs Stanford telomere startup Rejuvenation Technologies
What's the deal? Jetstream Venture FundDealroom has a profile for this one. Try Dealroom → has made an early-stage investment in Rejuvenation Technologies, a biotechnology startup developing targeted mRNA therapies designed to extend telomeres and restore cells' regenerative capacity. The deal was announced on September 24, 2026.
What's the endgame? Founded on research at Stanford UniversityDealroom has a profile for this one. Try Dealroom → by chief executive officer and co-inventor John Ramunas, the company delivers modified mRNA to specific organs via proprietary lipid nanoparticles. Unlike permanent telomerase activation, the approach transiently extends telomeres — aiming to reverse years of cellular aging in a single day.
The company is advancing preclinical pipelines targeting idiopathic pulmonary fibrosis and severe chronic liver disease. It is backed by Khosla Ventures and Y Combinator, plus more than $8 million in non-dilutive grants from the NIHDealroom has a profile for this one. Try Dealroom → and CIRMDealroom has a profile for this one. Try Dealroom →.
Why now? The investment expands Jetstream's longevity and regenerative medicine holdings, which already include Rejuvenate Bio, a Harvard-spun gene therapy company backed by Merck Animal HealthDealroom has a profile for this one. Try Dealroom →, and Wonderlab BioDealroom has a profile for this one. Try Dealroom →, which develops off-the-shelf cell therapies.
"Rejuvenation Technologies represents the kind of highly technical, paradigm-shifting science Jetstream seeks to identify early," said Chris Yoo, fund manager at Jetstream.
The signal: Jetstream is an interval fund managed by Xcellerant VenturesDealroom has a profile for this one. Try Dealroom → and Sweater Industries LLCDealroom has a profile for this one. Try Dealroom →, structured to give retail investors access to venture deals with lower minimums and no carried interest. The bet on early-stage longevity science reflects a wider push to open institutional-grade deal flow to mainstream investors.
Image credit: Generated with Gemini
